NDC product
VYLOY
NDC 0469-4425 · Astellas Pharma US, Inc.
Key facts
| Product NDC | 0469-4425 |
|---|---|
| Proprietary name | VYLOY |
| Nonproprietary name | ZOLBETUXIMAB |
| Substances | ZOLBETUXIMAB |
| Dosage form | INJECTION, POWDER, FOR SUSPENSION |
| Route | INTRAVENOUS |
| Labeler | Astellas Pharma US, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761365 |
| Pharmacologic classes | Claudin 18.2-directed Antibody Interactions [MoA], Claudin 18.2-directed Cytolytic Antibody [EPC] |
| Marketing start | Apr 24, 2025 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: